Neuphoria Therapeutics Inc [NEUP] stock is trading at $4.58, down -2.76%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The NEUP shares have gain 6.51% over the last week, with a monthly amount drifted -61.15%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Neuphoria Therapeutics Inc [NASDAQ: NEUP] stock has seen the most recent analyst activity on September 28, 2023, when H.C. Wainwright upgraded its rating to a Buy but kept the price target unchanged to $8 for it. Previously, Maxim Group reaffirmed its Buy rating on September 28, 2023, and elevated its price target to $10. On January 10, 2022, H.C. Wainwright initiated with a Buy rating and assigned a price target of $54 on the stock. Evercore ISI started tracking the stock assigning a Outperform rating and suggested a price target of $17 on January 10, 2022. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $52 as its price target on January 10, 2022. Berenberg started tracking with a Buy rating for this stock on January 10, 2022, and assigned it a price target of $21.
Neuphoria Therapeutics Inc [NEUP] stock has fluctuated between $2.16 and $21.40 over the past year. Neuphoria Therapeutics Inc [NASDAQ: NEUP] shares were valued at $4.58 at the most recent close of the market.
Analyzing the NEUP fundamentals
Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -0.05%, Pretax Profit Margin comes in at 0.36%, and Net Profit Margin reading is 0.37%. To continue investigating profitability, this company’s Return on Assets is posted at 0.19, Equity is 0.31 and Total Capital is -0.03. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.38 points at the first support level, and at 4.19 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.84, and for the 2nd resistance point, it is at 5.11.
Ratios To Look Out For
For context, Neuphoria Therapeutics Inc’s Current Ratio is 11.01. As well, the Quick Ratio is 11.01, while the Cash Ratio is 10.98. Considering the valuation of this stock, the price to sales ratio is 0.55, the price to book ratio is 0.33.
Transactions by insiders
Recent insider trading involved Lynx1 Capital Management LP, 10% Owner, that happened on Oct 21 ’25 when 0.64 million shares were purchased.
